Barinthus Biotherapeutics announced the appointment of Leon Hooftman, M.D., as Chief Medical Officer, CMO.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRNS:
- Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
- Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
- Barinthus price target lowered to $8 from $15 at H.C. Wainwright
- Barinthus Biotherapeutics announces 2024 upcoming milestones
- Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments